Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates

Financial Performance - Pulse Biosciences reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.32, representing an earnings surprise of +18.75% [1] - The company posted revenues of $0.26 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 5.60%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on $0.5 million in revenues, and for the current fiscal year, it is -$1.66 on $3.75 million in revenues [7] Stock Performance - Pulse Biosciences shares have increased by approximately 85.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Pulse Biosciences belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]